© 2001 by European Society of Cardiology
ICDS WORKING GROUP REPORT
Indications for implantable cardioverter defibrillator (ICD) therapy
Study Group on Guidelines on ICD of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology
Correspondence: R. N. W. Hauer, MD, Heart Lung Center Utrecht, University Medical Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
References
[1] Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303: 322–324.[Web of Science][Medline]
[2] Wever EFD, Hauer RNW, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995; 91: 2195–2203.
[3] Wever EFD, Hauer RNW, Schrijvers G, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors: a randomized study. Circulation 1996; 93: 489–496.
[4] Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with prior myocardial infarction, low ejection fraction and asymptomatic non-sustained ventricular tachycardia. N Engl J Med 1996; 335: 1933–1940.
[5] N Engl J Med 1997; 337: 1576–1583 The AVID investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias.
[6] Bigger JT Jr. for the CABG-Patch Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337: 1569–1575.
[7] Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748–754.
[8] Connolly SJ, Gent M, Roberts RS, et al. A randomized trial of the implantable cardioverter defibrillator against amiodarone. Canadian Implantable Defibrillator Study (CIDS). Circulation 2000; 101: 1297–1302.
[9] Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882–1890.
[10] Viskin S and Belhassen B. Idiopathic ventricular fibrillation. Am Heart J 1990; 120: 661–671.[CrossRef][Web of Science][Medline]
[11] Wever EFD, Hauer RNW, Oomen A, Peters RHJ, Bakker PFA, Robles de Medina EO. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation 1993; 88: 1021–1029.
[12] Schneider MAE, Siebels J, Rüppel R, Kuck KH. Idiopathic ventricular fibrillation: risk stratification and 24 months follow-up in 16 patients. Pacing Clin Electrophysiol 1993; 16: 949.
[13] Lévy S, Hauer RNW, Raviele A, Daubert JC, Campbell RWF, Breithardt G. on behalf of the Study Group on Qualification of ICD Implanting Centres of the working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology. Recommendations for qualification of centers implanting and following defibrillators. Eur Heart J 1996; 17: 1796–1799.
[14] Luu M, Stevenson WG, Stevenson WL, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80: 1675–1680.
[15] J Am Coll Cardiol 1998; 31: 1175–1209 ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation).
[16] Hohnloser SH, Andresen D, Block M, et al. Leitlinien zur Implantation von Defibrillatoren. Z Kardiol 2000; 89: 126–135.[CrossRef]
[17] Mirowski M, Reid PR, Winkle RA, et al. Mortality in patients with implanted automatic defibrillators. Ann Int Med 1983; 98: 585–588.[Web of Science][Medline]
[18] Böcker D, Block M, Isbruch F, et al. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol 1993; 21: 1638–1648.[Abstract]
[19] Powel AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter defibrillators on the long-term prognosis of survivors of out of hospital cardiac arrest. Circulation 1993; 88: 1083–1092.
[20] Böcker D, Haverkamp W, Block M, Borggrefe M, Breithardt G. Comparison of d,l sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996; 94: 151–157.
[21] Nicklas JM, McKenna WJ, Stewart RA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016–1021.[CrossRef][Web of Science][Medline]
[22] Johnson RA and Palacios I. Dilated cardiomyopathies of the adult (first of two parts). N Engl J Med 1982; 307: 1051–1058.[Web of Science][Medline]
[23] Knight BP, Strickberger SA, Daoud EG, et al. Outcome of patients with non-ischemic dilated cardiomyopathy and unexplained syncope treated with an implantable cardioverter defibrillator. Circulation 1997; 96: 708.
[24] Milner PG, DiMarco JP, Lerman BB. Electrophysiological evaluation of sustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. Pacing Clin Electrophysiol 1998; 11: 562–568.
[25] Böcker D, Bänsch D, Heinecke A, et al. Potential benefit from ICD therapy in patients with and without heart failure. Circulation 1998; 98: 1636–1643.
[26] McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11: 147–153.[Abstract]
[27] Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med 1988; 318: 1255–1257.[Web of Science][Medline]
[28] Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365–373.
[29] Hauer RNW and Wilde AAM. Mitral valve prolapse. In Zipes DP and Jalife J (Eds.). Cardiac electrophysiology. From cell to bedside 1995; 833–837.
[30] Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J 1985; 109: 399–411.[CrossRef][Web of Science][Medline]
[31] Priori SG, Barhanin J, Hauer RNW, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management. Eur Heart J 1999; 20: 174–195.
[32] Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of ß-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101: 616–623.
[33] Bardy GH Jr and Borggrefe M, et al. Survivors of out of hospital cardiac arrest with apparently normal heart: need for definition and standardized clinical evaluation. Consensus statement of the Joint Steering Committees of UCARE and of IVF-US. Circulation 1997; 95: 265–272.
[34] Brugada P and Brugada J. Right bundle branch block, persistent ST-segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992; 20: 1391–1396.[Abstract]
[35] Block M and Breithardt G. Implantable cardioverter defibrillators: clinical aspects. In Zipes DP and Jalife J (Eds.). Cardiac electrophysiology: from cell to bedside 2000; Philadelpha W.B. Saunders Company pp. 958–970.
[36] Raitt MH, Dolack GL, Kudenchuk PJ, et al. Ventricular arrhythmias detected after transvenous defibrillator implantation in patients with a clinical history of only ventricular fibrillation: implications for use of implantable defibrillator. Circulation 1995; 91: 1996–2001.
[37] Zaim S, Zaim B, Rottman J, et al. Characterization of spontaneous recurrent ventricular arrhythmias detected by electrogram-storing defibrillators in sudden cardiac death survivors with no inducible ventricular arrhythmias at baseline electrophysiologic testing. Am Heart J 1996; 132: 274–279.[CrossRef][Web of Science][Medline]
[38] Mitra RL, Hsia HH, Hook BG, et al. Efficacy of antitachycardia pacing in patients with cardiac arrest. PACE 1995; 18: 2035–2040.
[39] Mont L, Valentino M, Sambola A, Matas M, Aguinaga L, Brugada J. Arrhythmia recurrence in patients with a healed myocardial infarction who received an implantable defibrillator: analysis according to the clinical presentation. J Am Coll Cardiol 1999; 34: 351–357.
[40] Rosenqvist M, Beyer T, Block M, de Dulk K, Minten J, Lindemans F. Adverse events with transvenous inplantable cardioverter-defibrillators: a prospective multicenter study. Circulation 1998; 98: 663–670.
[41] Swerdlow CD, Chen PS, Kass RM, et al. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol 1994; 23: 1342–1355.[Abstract]
[42] Neuzner J, Pitschner HF, Schlepper M. Programmable VT detection enhancements in implantable cardioverter defibrillator therapy. Pacing Clin Electrophysiol 1995; 18:(Suppl II), 539–547.[CrossRef][Medline]
[43] Schaumann A, von zur Muhlen F, Gonska BD, Kreuzer H. Enhanced detection criteria in implantable cardioverter-defibrillators to avoid inappropriate therapy. Am J Cardiol 1996; 78:(5A) 42–50.[Web of Science][Medline]
[44] Brugada J, Mont L, Figueiredo M, Valentino M, Matas M, Navarro-Lopez F. Enhanced detection criteria in implantable defibrillators. J Cardiovasc Electrophysiol 1998; 9: 262–268.
[45] Weber M, Böcker D, Bänsch D, et al. Efficacy and safety of the initial use of stability and onset criteria in implantable cardioverter defibrillator. J Cardiovasc Electrophsyiol 1999; 10: 145–153.[Web of Science][Medline]
[46] Brachmann J, Swerdlow CD, Mitchell BD, et al. Worldwide experience with the electrogram width feature for improved detection in an implantable pacer-cardioverter-defibrillator. J Am Coll Cardiol 1997; 29:(Suppl A), 115A.
[47] Duru F, Schonbeck M, Lüscher TF, Candinas R. The potential for inappropriate ventricular tachycardia confirmation using the Intracardiac Electrogram (EGM) Width Criterion. Pacing Clin Electrophysiol 1999; 22: 1039–1046.[CrossRef][Medline]
[48] Herwig S, Jung W, Wolpert C, et al. First results with a new morphology criterion for discrimination of supraventricular and ventricular tachycardias. J Am Coll Cardiol 2000; 35:(Suppl A), 127A (Abstract).
[49] Lavergne T, Daubert JC, Chauvin M, et al. Preliminary clinical experience with the first dual chamber pacemaker defibrillator. Pacing Clin Electrophysiol 1997; 20:(Suppl), 182–188.[CrossRef][Medline]
[50] Kühlkamp V, Wilkoff BL, Brown AB. 7271 Gem DR Worldwide Investigators, Experience with a new dual chamber implantable defibrillator.
[51] Schaumann A, von zur Muhlen F, Herse B, Gonska BD, Kreuzer H. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 1998; 97: 67–74.
[52] Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 2000; 11: 593–600.[Web of Science][Medline]
[53] Wietholt D. First results of the Prevent study.
[54] Leclerq C, Cazeau S, le Breton H, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. J Am Coll Cardiol 1998; 32: 1825–1831.
[55] Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999; 99: 2993–3001.[Medline]
[56] Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: 2927–2933.[Medline]
[57] Gadler F, Linde C, Daubert C, et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing in cardiomyopathy. Eur Heart J 1999; 20: 1044–1050.
[58] Swerdlow CD, Schöls W, Dijkman B, et al. Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter-defibrillator. Circulation 2000; 101: 878–885.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. Pedersen, R. T. van Domburg, D. A. M. J. Theuns, L. Jordaens, and R. A. M. Erdman Type D Personality Is Associated With Increased Anxiety and Depressive Symptoms in Patients With an Implantable Cardioverter Defibrillator and Their Partners Psychosom Med, September 1, 2004; 66(5): 714 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Priori From trials to guidelines to clinical practice: the need for improvement Europace, January 1, 2004; 6(3): 176 - 178. [Full Text] [PDF]
|
|
|
|
|
|
A. Przybylski, R. Baranowski, J. J. Zebrowski, and H. Szwed Verification of implantable cardioverter defibrillator (ICD) interventions by nonlinear analysis of heart rate variability - preliminary results Europace, January 1, 2004; 6(6): 617 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. M. J. Theuns, J. C. J. Res, and L. J. Jordaens Home monitoring in ICD therapy: future perspectives Europace, January 1, 2003; 5(2): 139 - 142. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||